STOCK TITAN
  1. Home
  2. Sec-filings
  3. ATXI
  4. [EFFECT] AVENUE THERAPEUTICS, INC. SEC Filing

[EFFECT] AVENUE THERAPEUTICS, INC. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: December 16, 2025
Accession Number: 0001104659-25-121247
Submission Type: POS AM
CIK: 0001644963
Company Name: AVENUE THERAPEUTICS, INC.
File Number: 333-279125

Source: View Original Filing on SEC EDGAR

Stock ATXI logo
Avenue Therapeutics Inc

OTC:ATXI

ATXI Rankings

#6847 Ranked by Market Cap
N/A Ranked by Dividends

ATXI Latest News

Feb 23, 2026
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
Nov 6, 2025
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
Nov 14, 2024
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Oct 9, 2024
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
Sep 3, 2024
Avenue Therapeutics to Participate in Upcoming Investor Conferences

ATXI Latest SEC Filings

Feb 23, 2026
[8-K] AVENUE THERAPEUTICS, INC. Reports Material Event
Feb 17, 2026
[SCHEDULE 13G/A] AVENUE THERAPEUTICS, INC. Amended Passive Investment Disclosure
Jan 6, 2026
[SCHEDULE 13D/A] AVENUE THERAPEUTICS, INC. SEC Filing
Jan 6, 2026
[Form 4] AVENUE THERAPEUTICS, INC. Insider Trading Activity
Dec 31, 2025
[8-K] AVENUE THERAPEUTICS, INC. Reports Material Event

ATXI Stock Data

2.79M
2.72M
Biotechnology
Pharmaceutical Preparations
Link
United States
BAY HARBOR ISLANDS